- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00155766
Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)
A Pilot Study for the Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs) Pulsed With Human Papillomavirus Type 16 E7 Antigen
Chemotherapy is the current standard treatment for unresectable recurrent cervical carcinoma after radiotherapy or distant metastasis of cervical carcinoma. The most effective regimens are cisplatin-based chemotherapy. After failure of the cisplatin-based chemotherapy, there is still no treatment that has been proved to be effective.
Human papilloma viruses (HPV) have been consistently implicated in causing cervical cancer especially those high-risk types (HPV 16,18,31,45) have been strongly associated with cervical cancer. HPV 16 was found in more than 50% of cervical cancer tissues. Results from many animal tumor models have indicated that immunization with tumor antigen-pulsed dendritic cells can trigger a long-lasting anti-tumor immune response and significantly inhibit the growth of implanted tumor cells. Recently, many clinical trials have been conducted to evaluate the feasibility and safety of immunizing cancer patients with tumor antigen-pulsed dendritic cells. No severe toxicity has been reported and some patients were shown to respond to the treatment. Based on previous animal and clinical studies by other investigators, we propose to evaluate the potential of immunizing cancer patients with antigen-pulsed autologous dendritic cells as a cancer vaccine to treat for recurrent cervical cancers after failure of cisplatin-based chemotherapy treatment or refusing chemotherapy. In this study, we will generate dendritic cells by culturing patient's autologous PBMC with GM-CSF and IL-4 in vitro. These dendritic cells will be pulsed with synthetic peptides representing the CTL epitopes on HPV Type 16 E7. Antigen-pulsed dendritic cells will be injected into inguinal lymph nodes under the guidance of real-time sonography. Each patient will receive four injections and 12 patients in total will be recruited for this study.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Chemotherapy is the current standard treatment for unresectable recurrent cervical carcinoma after radiotherapy or distant metastasis of cervical carcinoma. The most effective regimens are cisplatin-based chemotherapy. After failure of the cisplatin-based chemotherapy, there is still no treatment that has been proved to be effective.
Human papilloma viruses (HPV) have been consistently implicated in causing cervical cancer especially those high-risk types (HPV 16,18,31,45) have been strongly associated with cervical cancer. HPV 16 was found in more than 50% of cervical cancer tissues. Results from many animal tumor models have indicated that immunization with tumor antigen-pulsed dendritic cells can trigger a long-lasting anti-tumor immune response and significantly inhibit the growth of implanted tumor cells. Recently, many clinical trials have been conducted to evaluate the feasibility and safety of immunizing cancer patients with tumor antigen-pulsed dendritic cells. No severe toxicity has been reported and some patients were shown to respond to the treatment. Based on previous animal and clinical studies by other investigators, we propose to evaluate the potential of immunizing cancer patients with antigen-pulsed autologous dendritic cells as a cancer vaccine to treat for recurrent cervical cancers after failure of cisplatin-based chemotherapy treatment or refusing chemotherapy. In this study, we will generate dendritic cells by culturing patient's autologous PBMC with GM-CSF and IL-4 in vitro. These dendritic cells will be pulsed with synthetic peptides representing the CTL epitopes on HPV Type 16 E7. Antigen-pulsed dendritic cells will be injected into inguinal lymph nodes under the guidance of real-time sonography. Each patient will receive four injections and 12 patients in total will be recruited for this study.
Studientyp
Einschreibung
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Taipei, Taiwan
- Rekrutierung
- National Taiwan University Hospital
-
Kontakt:
- Chi-An Chen, MD
- Telefonnummer: 5157 886-2-2312-3456
- E-Mail: cachen@ha.mc.ntu.edu.tw
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- recurrent cervical cancer
- HPV 16 infection
- Previously received cisplatin ot 5-FU based chemotherapy or refused to receive chemotherapy
- HLA-A2 haplotype
- Older than 20 years old
- ECOG I or II
- Life expectancy longer than 3 months
- Adequate bone marrow reserve
- pregnancy test: negative
- Informed consent obtained
Exclusion Criteria:
- CNS metastasis
- Acute or chronic infection
- Pregnant or lactating women
- Asthma
- Cardiac diseases such as heart failure, unstable angina, arrhythmia, myocardial infarction
- Autoimmune disease
- Previously other cancers (except basal cell cancer)
- Without chemotherapy, biotherapy for more than 6 weeks
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
---|
1. Safety issues in patients receiving HPV16 E7 peptide-pulsed autologous DCs immunotherapy
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
---|
1. Immunologic responses in patients receiving HPV16 E7 peptide-pulsed autologous DCs immunotherapy
|
2. Clinical response in patients receiving HPV16 E7 peptide-pulsed autologous DCs immunotherapy
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Chi-An Chen, MD, National Taiwan University Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 9100205963
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Gebärmutterhalskrebs
-
Tanta UniversityNoch keine RekrutierungSchilddrüsenchirurgie | Verbesserte Wiederherstellung | Bilateraler ultraschallgeführter oberflächlicher Plexus-Cervical-Block
-
Khon Kaen UniversityBeendetHumane Papillomavirus-Clearance nach 12 MonatenThailand
-
Orthofix Inc.AbgeschlossenDegenerative Bandscheibenerkrankungen | Vertebral Cervical Fusion SyndromeVereinigte Staaten
-
University Hospital, LinkoepingAhmed Mohamed Abdelrahman; Mahmoud Ahmed Mewafy; Abdelrhman Alshawadfy; Haidi Abd-Elzaher und andere MitarbeiterAbgeschlossenPostoperative Schmerzen | Analgesie durch lokale Wundinfiltration von Lidocain | Analgesie mit einer ultraschallgeführten Plexus-Cervical-Blockade unter Verwendung von LidocainSchweden
Klinische Studien zur HPV16 E7 peptide-pulsed autologous DCs
-
National Cancer Institute (NCI)AbgeschlossenHautmelanom im Stadium IV | Wiederkehrendes Melanom | Hautmelanom im Stadium IIIB | Hautmelanom im Stadium IIIC | Hautmelanom im Stadium IIA | Hautmelanom im Stadium IIB | Hautmelanom im Stadium IIC | Hautmelanom im Stadium IIIA | Hautmelanom im Stadium IA | Hautmelanom im Stadium IBVereinigte Staaten